Refine by
Drug Designation Articles & Analysis
209 news found
In the ever-evolving landscape of pharmaceutical research and development, the demand for innovative and efficient drug discovery methods is more pressing than ever. At the forefront of this demanding field is Protheragen-ING AI-Pharma, a contract research and development biotechnology company, offering cutting-edge solutions to researchers through its AI-powered ...
Among the various materials used in medical device design, polytetrafluoroethylene (PTFE tubing) has emerged as a standout choice, particularly in applications such as catheters and drug delivery systems. ...
Unfortunately, existing drug formulations for glaucoma often have low bioavailability and inconsistent drug release rates. ...
CD ComputaBio, a pioneering provider of computational biology services, has recently introduced its advanced Computer-Aided Drug Design (CADD) services, revolutionizing the drug discovery landscape. ...
They’re widely used as drug carriers mainly because of their ability to efficiently carry and release drug molecules, thereby improving drug bioavailability and therapeutic efficacy. The design of such drug carriers also helps to overcome some of the limitations of conventional drugs such ...
In response to our positive initial data, the US Food and Drug Administration (FDA) awarded our HLHS program with three distinct and important designations: Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designation, each of which offer benefits to our development and ...
Controlled-release drug delivery systems are designed to release medications at a desired rate and duration, ensuring consistent therapeutic levels in the body. ...
CD ComputaBio's Antibody De Novo Design technology aims to transform this landscape, offering a more efficient and cost-effective approach to drug development. ...
In the realm of Antibody Drug Design Services, CD ComputaBio employs sophisticated computational methodologies to engineer antibodies of unparalleled precision and efficacy. ...
This approach is poised to revolutionize the field of drug discovery by offering researchers an efficient and cost-effective solution for identifying promising drug candidates. ...
Recently, the company introduced a series of state-of-the-art services in Drug Design and Computer-Aided Drug Design (CADD) with the aim of providing efficient and reliable solutions for the pharmaceutical industry's drug development endeavors. Drug Design is a crucial ...
The company is pleased to announce the launch of the Protein-Small Molecule Docking service, designed to help customers quickly and accurately design and screen drugs. ...
As a widely used and trusted molecular docking software, AutoDock simplifies molecular docking simulations and improves the accuracy of drug development. This software is widely used by researchers to simulate and predict the interaction between small molecules and the protein of interest, a fundamental technique for drug discovery and development. ...
Biolojic uses its proprietary AI platform to design antibodies with new capabilities to cure disease, ushering in a new era of smart therapeutics Biolojic Tel Aviv to focus on computational design of antibodies; Boston location will focus on drug development Biolojic Design, a unique technology company pioneering ...
Possessing a powerful team of experts in chemistry, biology, mathematics, crystallography, and pharmacology, Alfa Chemistry focuses on combining the power of computational chemistry with a variety of research focuses on supporting Computer Aided Drug Design, Thermodynamic Calculation, Fluorescence Spectrum Prediction, and applications that accelerate novel ...
Commercial and Pipeline Update Product portfolio Acute Care Hospital: RYANODEX®, vasopressin, Barhemsys®, Byfavo® Oncology: BENDEKA, BELRAPZO, PEMFEXY11, TREAKISYM Japan12 75-person commercial team covers all products excluding BENDEKA and TREAKISYM Company projects growth in earnings while still supporting R&D Cash flow from legacy products expected to continue to ...
The company has recently announced the introduction of its Autodock Vina software, designed to predict the mechanism of small molecules, such as substrates or drug candidates, binding to receptors with known 3D structures. ...
The Flare™ structure-based and ligand-based drug design platform has a plugin interface that enables incorporation of cutting-edge third-party software (including OpenMM) to introduce new capabilities. ...
RenovoRx designed this technology based on evidence that administering chemotherapy in this way may shrink or stabilize certain types of cancer. ...
ByxCures
LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA. On December 1, 2022, the US FDA notified LISCure of the orphan drug designation of LB-P8, LISCure's microbiome novel ...